| Literature DB >> 26238094 |
Antonio Naranjo1, Laura Cáceres2, José Ángel Hernández-Beriaín3, Félix Francisco2, Soledad Ojeda2, Sigrid Talaverano4, Javier Nóvoa-Medina3, José Adán Martín4, Esmeralda Delgado5, Elisa Trujillo5, Fátima Álvarez6, Laura Magdalena6, Carlos Rodríguez-Lozano2.
Abstract
The aim of the present study was to analyse the patterns of treatment adjustment in rheumatoid arthritis (RA) patients with active disease in routine clinical care. This was a cross-sectional study of consecutive patients with RA conducted in five hospitals. Activity scales (DAS28-ESR) and function (HAQ) were measured, as well as whether ultrasound was performed as part of the assessment. Treatment decision (no changes/reduction/intensification) and time to the next scheduled visit were the outcomes variables. Associated factors were analysed by multilevel regression models. A total of 343 patients were included (77 % women, mean age 57 years, mean RA duration 10 years), of whom 44 % were in remission by DAS28. Treatment was continued in 202 (59 %) patients, reduced in 57 (16 %), and intensified in 83 (24 %). In the 117 patients with active RA (DAS28 ≥ 3.2), treatment was intensified in 61 (52 %). Factors associated with treatment intensification were physician and patient VAS, and DAS28, but not the centre. In the multilevel regression analysis with intensification of treatment as dependent variable, the following factors were significantly associated: DAS28 [OR 3.67 (95 % CI 2.43-5.52)], patient VAS [OR 1.04 (95 % CI 1.01-1.08)], and have performed an ultrasound [OR 3.36 (95 % CI 1.47-7.68)]. Factors associated with time to the next scheduled visit (an average of 4.3 months) were patient and physician VAS, DAS28, and centre. In clinical practice, half of the patients with active RA maintain or reduce the treatment. The decision to intensify treatment in active RA as recommended by a treat-to-target strategy is complex in practice.Entities:
Keywords: DAS28; Rheumatoid arthritis; Treat to target; Ultrasonography
Mesh:
Substances:
Year: 2015 PMID: 26238094 DOI: 10.1007/s00296-015-3332-z
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631